IP Verse

A Rapamycin Derivative For Treating Lung Cancer - EP3143995

The patent EP3143995 was granted to Novartis on Jan 15, 2025. The application was originally filed on Feb 18, 2002 under application number EP16186041A. The patent is currently recorded with a legal status of "Patent Maintained As Amended".

EP3143995

NOVARTIS
Application Number
EP16186041A
Filing Date
Feb 18, 2002
Status
Patent Maintained As Amended
Dec 13, 2024
Grant Date
Jan 15, 2025
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (7)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

ACCORD HEALTHCARESep 5, 2019PLOUGMANN VINGTOFTADMISSIBLE
GENERICS UKSep 5, 2019ELKINGTON AND FIFEWITHDRAWN
STADA ARZNEIMITTELSep 5, 2019HAMM & WITTKOPPWITHDRAWN
ZENTIVA KSSep 3, 2019BIRD & BIRDADMISSIBLE
TEVA PHARMACEUTICALSAug 30, 2019GREINERADMISSIBLE
SYNTHONAug 27, 2019BENNEKERADMISSIBLE
ETHYPHARMJun 12, 2019LLRADMISSIBLE

Patent Citations (16) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
OPPOSITIONEP1064942
OPPOSITIONEP2793686
OPPOSITIONEP3143995
OPPOSITIONGB104072
OPPOSITIONGB124957
OPPOSITIONUS4885171
OPPOSITIONUS5206018
OPPOSITIONUS5672605
OPPOSITIONUS5985325
OPPOSITIONWO0151049
OPPOSITIONWO02066019
OPPOSITIONWO9409010
OPPOSITIONWO9725977
OPPOSITIONWO9747317
SEARCHWO0151049
SEARCHWO9747317

Non-Patent Literature (NPL) Citations (61) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- ALEXANDRE J et al., "la rapamycinr et le CCI-779", Bull Cancer, (19990000), vol. 86, no. 10, pages 808 - 811, XP055639345-
OPPOSITION- BEUVINK, "Antitumor Activity of RAD001 , an Orally Active Rapamycin Derivative", Proc Am Assoc Cancer Research, (20010300), XP001093826-
OPPOSITION- BEUVINK et al., ""ANTITUMOR ACTIVITY OF RAD001, AN ORALLY ACTIVE RAPAMYCIN DERIVATIVE", Proceedings of the American Association for Cancer Research, (20010000), vol. 42, page 366, XP001093826-
OPPOSITION- BEUVINK et al., "ANTITUMOR ACTIVITY OF RAD001, AN ORALLY ACTIVE RAPAMYCIN DERIVATIVE", Proceedings of the American Association for Cancer Research, (20010324), vol. 42, page 366, XP001093826-
OPPOSITION- BEUVINK, I et al., "ANTITUMOR ACTIVITY OF RAD001, AN ORALLY ACTIVE RAPAMYCIN DERIVATIVE", Proc. Am. Ass. Cancer Research, (20010300), vol. 42, page 366, XP001093826-
OPPOSITION- BEUVINK, I. et al., "ANTITUMOR ACTIVITY OF RAD001, AN ORALLY ACTIVE RAPAMYCIN DERIVATIVE", Proc. Am. Ass. Cancer Research, (20010300), vol. 42, page 366, XP001093826-
OPPOSITION- "bronchus", Wikipedia, (20190714), XP055639340-
OPPOSITION- CROWE et al., "Absorption and intestinal metabolism of SDZ- RAD and raoamvcin in rats", Drug Metabolism and Disposition, (19990000), vol. 27, no. 5, pages 627 - 635, XP055449375-
OPPOSITION- CROWE et al., ""Absorption and intestinal metabolism of SDZ-RAD and rapamycin in rats", Drug Metabolism and Disposition, (19990000), vol. 27, no. 5, pages 627 - 635, XP055449375-
OPPOSITION- CROWE et al., "Absorption and intestinal metabolism of SDZ-RAD and rapamycin in rats", Drug Metabolism and Disposition, (19990000), vol. 27, no. 5, pages 627 - 635, XP055449375-
OPPOSITION- DUMONT, "Everolimus Novartis", CURR OPIN INVESTIG DRUGS, (20010000), vol. 2, pages 1220 - 1234, XP055639440-
OPPOSITION- ENG et al., "ACTIVITY OF RAPAMYCIN (AY-22,989) AGAINST TRANSPLANTED TUMORS", The Journal of Antibiotics, (19840000), vol. 37, no. 10, pages 1231 - 1237, XP001095310-
OPPOSITION- ENG et al., "ACTIVITY OF RAPAMYCIN (AY-22,989) AGAINST TRANSPLANTED TUMORS", The Journal of Antibiotics, (19840000), vol. XXXVII, no. 10, pages 1231 - 1237, XP001095310-
OPPOSITION- GIBBONS et al., Proceedings of the American Association for Cancer Research, (19990000), vol. 40, page 301, XP001071222-
OPPOSITION- GIBBONS et al., "The effect of CCI-779, a novel macrolide anti-tumor agent, on the growth of human tumor cells in vitro and nude mouse xenografts in vivo", Proceedings of the American Association for Cancer Research, (19990000), vol. 40, page 301, XP001071222-
OPPOSITION- GUBA et al., "Rapamycin inhibiert das Tumorwachstum und die Tumormetastasierung fiber Antiangiogenese", Chirurgisches, (2001), vol. 30, pages 37 - 39, XP055422819-
OPPOSITION- GUBA et al., "Rapamycin inhibiert das Tumorwachstum und die Tumormetastasierung fiber Antiangiogenese", Chirurgisches Forum, (20010000), vol. 30, pages 37 - 39, XP055422819-
OPPOSITION- GUBA et al., "Rapamycin inhibiert das Tumorwachstum und die Tumormetastasierung fiber Antiangiogenese", Chirurgisches Forum 2001 für experimentelle und klinische Forschung,, (20010000), pages 37 - 39, XP055422819-
OPPOSITION- HIDALGO, M. et al., "Abstarct 726 CCI-779, a Rapamycin Analog with Multifaceted Inhibitor of Signal Transducion: a Phase I Study", Proceedings ASCO, Clinical Pharmacology, page 187a, XP009193117-
OPPOSITION- HIDALOO et al., "The rapamycin-sensitive signal transduction pathway as a target for cancer therapy", Oncoaene, (20000000), vol. 19, pages 6680 - 6686, XP055640403-
OPPOSITION- Irvin D. Fleming et al.,, AJCC Cancer Staging Manual, Fifth Edition, Lippincott-Raven Publishers, (19970000), pages 5pp, xiv-xv, 3-9, 127-133, 135 - 137, XP055640079-
OPPOSITION- Iwan BEUVINK et al., "#1972- Antitumor Activity of RAD001, an Orally Active Repamycin Derivative", Proceedings of the American Association for Cancer Research, (20010000), vol. 42, page 366, XP055621157-
OPPOSITION- MCMAHON et al., "High-throughput analysis of everolimus (RADOOl) and cyclosporin A (CsA) in whole blood by liquid chromatography/mass spectrometry using a semi-automated 96-well solid-phase extraction system", Rapid Commun. Mass. Spectrom., (20000000), vol. 14, pages 1965 - 1971, XP055639343-
OPPOSITION- MCMAHON, "High-throughput Analysis of Everolimus (RAD001) and Cyclosporine A (CSA) in Whole Blood by Liquid Chromatography/Mass Spectrometry Using a Semi- Automated 96-Well Solid-Phase Extraction System", Rapid Commun. Mass Spectrom., (20000000), vol. 14, pages 1965 - 1971, XP055639343-
OPPOSITION- RAYMOND, E. et al., "abstract 728 CCI-779, a Rapamycin Analog with Antitumor Activity: A Phase I Study Utilizing a Weekly Schedule", Thirty-Sixth Annual Meeting of the American Society of Clinical Oncology, vol. 19, page 187a, XP055422938-
OPPOSITION- R. E. MORRIS, "Rapamycins: antifungal, antitumor, antiproliferative, and immunosuppressive macrolides", Transplantation Reviews, (19920000), vol. 6, no. 1, pages 39 - 87, XP009110318-
OPPOSITION- "respiration", Guyton, textbook of medical physiology, 1986, pages 474 - 475, XP055639348-
OPPOSITION- R.M. HOFFMAN, "Orthotopic metastatic mouse for anticancer drug discovery and evolution:a bridge to the clinic", Investigational New Drugs, (19990000), vol. 17, pages 343 - 359, XP055639400-
OPPOSITION- Robert M. HOFFMANN, "Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic", Investigational New Drugs, (19990000), vol. 17, no. 4, pages 343 - 359, XP055640217-
OPPOSITION- Sarah H. LANDIS et al., "Cancer Statistics, 1999", CA- Cancer Journal for Clinicians, (19990100), vol. 49, no. 1, pages 8 - 31, XP055640205-
OPPOSITION- SEUFFERLEIN et al., "Rapamycin inhibits constitutive p70-s6k phosphorylation, cell proliferation, and colony formation in small cell lung cancer cells", Cancer Research, (19960000), vol. 56, no. 17, pages 3895 - 3897, XP002766076-
OPPOSITION- SEUFFERLEIN et al., "Rapamycin inhibits constitutive p70-s6k phosphorylation, cell proliferation, and colony formation in small cell lung cancer cells"", Cancer Research, (19960000), vol. 56, pages 3895 - 3897, XP002766076-
OPPOSITION- SEUFFERLEIN et al., "Rapamycin inhibits constitutive p70-s6k phosphorylation, cell proliferation, and colony formation in small cell lung cancer cells", Cancer Research, (19960000), vol. 56, pages 3895 - 3897, XP002766076-
OPPOSITION- SEUFFERLEIN et al., "Rapamycin inhibits constitutive p70(s6k) phosphorylation, cell proliferation, and colony formation in small cell lung", Cancer Research, (19960901), vol. 56, no. 17, pages 3895 - 3897, XP002766072-
OPPOSITION- SEUFFERLEIN, TH. et al., "Rapamycin inhibits constitutive p70-s6k phosphorylation, cell proliferation, and colony formation in small cell lung cancer cells", J. Cancer Res, (19960000), vol. 56, pages 3895 - 3897, XP002766076-
OPPOSITION- SORBERRA et al., "SDZ-RAD Immunosuppressant", Drugs of the Future, (19990000), vol. 24, no. 1, pages 22 - 29, XP055640391-
OPPOSITION- "The Pathology of Cancer", Robert MCKINNELL et al., The biological basis of cancer, Cambridge University Press, (19980000), pages 2pp, 24 - 29, XP055640196-
OPPOSITION- ZHONG et al., "MODULATION OF HYPOXIA-INDUCIBLE FACTOR 1ALPHA EXPRESSION BY THE EPIDERMAL GROWTH FACTOR-PHOSPHATIDYLINOSITOL 3-KINASE/PTEN/AKT/FRAPPATHWAY IN HUMAN PROSTATE CANCER CELLS: IMPLICATIONS FOR TUMOR ANGIOGENESIS AND THERAPEUTICS", Cancer Research, (20000000), vol. 60, pages 1541 - 1545, XP002931192-
OPPOSITION- SEDRANI et al., "Chemical modification of rapamycin: the discovery of SDZ RAD", Transplantation Proceedings, (19980000), vol. 30, pages 2192 - 2194, XP000925138
OPPOSITION- SEDRANI et al., "CHEMICAL MODIFICATION OF RAPAMYCIN: THE DISCOVERY OF SDZ RAD", Transplantation Proceedings, (19980000), vol. 30, pages 2192 - 2194, XP000925138
OPPOSITION- SEDRANI, R. et al., "Chemical modification of rapamycin: the discovery of SDZ RAD", Transplantation Proceedings, (19980000), vol. 30, pages 2192 - 2194, XP000925138
OPPOSITION- HUTCHINSON, "OncologyCCI-779: a new targeted anticancer agent", The Lancet Oncology, (20000000), vol. 1, page 19 8, XP004813934
OPPOSITION- HIDALGO et al., "he rapamycin-sensitive signal transduction pathway as a target for cancer therapy", Oncogen, (20000000), vol. 19, pages 6680 - 6696, XP009002368
OPPOSITION- HIDALGO et al., "he rapamycin-sensitive signal transduction pathway as a target for cancer therapy", Oncogene, (20000000), vol. 19, pages 6680 - 6686, XP009002368
OPPOSITION- HIDALGO et al., "The rapamycin-sensitive signal transduction pathway as a target for cancer therapy", Oncogen, (20000000), vol. 19, pages 6680 - 6696, XP009002368
OPPOSITION- HIDALGO et al., "The rapamycin-sensitive signal transduction pathway as a target for cancer therapy", Oncogene, (20001227), vol. 19, no. 56, pages 6680 - 6686, XP009002368
OPPOSITION- HIDALGO, M. et al., "The rapamycin-sensitive signal transduction pathway as a target for cancer therapy", Oncogene, (20000000), vol. 19, doi:doi:10.1038/sj.onc.1204091, pages 6680 - 6686, XP009002368
OPPOSITION- HIDALGO, "The rapamycin-sensitive signal transduction pathway as a target for cancer therapy", Oncogen, (20000000), vol. 19, pages 6680 - 6696, XP009002368
OPPOSITION- HUANG, S. et al., "Mechanisms of resistance to rapamycins", Drug Resistance Updates, (20011200), vol. 4, no. 6, pages 378 - 391, XP001094520
OPPOSITION- MAJEWSKI et al., "THE IMMUNOSUPPRESSIVE MACROLIDE RAD INHIBITS GROWTH OF HUMAN EPSTEIN-BARR VIRUS-TRANSFORMED B LYMPHOCYTES IN VITRO AND IN VIVO: A POTENTIAL APPROACH TO PREVENTION AND TREATMENT OF POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDERS", PNAS, (20000000), vol. 97, no. 8, pages 4285 - 4290, XP001093844
OPPOSITION- SCHULER et al., "SDZ D5 A NEW RAPAMYCIN DERIVATIVE", Transplantation, (19970000), vol. 64, pages 36 - 42, XP002048032
OPPOSITION- SCHULER et al., "SDZ RAD, a new rapamycin derivative", Transplantation, (19970000), vol. 64, doi:10.1097/00007890-199707150-00008, pages 36 - 42, XP002048032
OPPOSITION- SCHULER et al., "SDZ RAD, a new rapamycin derivative", Transplantation, (19970000), vol. 64, no. 1, pages 36 - 42, XP002048032
OPPOSITION- SCHULER et al., "SDZ RAD, a new rapamycin derivative", Transplantation, (19970000), vol. 64, no. 36, page 42, XP002048032
OPPOSITION- SCHULER, W. et al., "SDZ RAD, A NEW RAPAMYCIN DERIVATIVE", Transplantation, (19970000), vol. 64, pages 36 - 42, XP002048032
SEARCH- HIDALGO M ET AL, "A phase I and pharmacological study of CCI-779, a rapamycin ester cell cycle inhibitor. ADIS TITLE: CCI 779: therapeutic use Solid tumours Phase I trial", ADISCTI, (200001), Database accession no. 2000:23473, URL: STN, XP002766113 [A] 1-4 * the whole document *-
SEARCH[ ] - HIDALGO M ET AL, "A phase I and pharmacological study of CCI-779, a rapamycin ester cell cycle inhibitor. ADIS TITLE: CCI 779: therapeutic use Solid tumours Phase I trial", ANNALS OF ONCOLOGY ( JAN 1, 2000 ), VOL. 11 (SUPPL. 4), PP. 133 (PLUS ORAL PRESENTATION) ABSTR. 606 MEETING INFO: CONGRESS OF THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY (25TH : OCTOBER 2000 : HAMBURG, GERMANY) ISSN: 0923-7534, (20000520), vol. 19, page 187, XP009193116-
SEARCH[ ] - HIDALGO M ET AL, "CCI-779, a rapamycin analog and multifaceted inhibitor of signal transduction: a phase I study. ADIS TITLE: CCI 779: therapeutic use Solid tumours Phase I trial", 36TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY ( MAY 20, 2000 ), VOL. 19, PP. 187 (PLUS POSTER) MEETING INFO: ANNUAL MEETING OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (36TH : MAY 2000 : NEW ORLEANS, LOUISIANA, USA), (20000520), vol. 19, page 187, XP009193117-
SEARCH- HIDALGO M ET AL, "CCI-779, a rapamycin analog and multifaceted inhibitor of signal transduction: a phase I study. ADIS TITLE: CCI 779: therapeutic use Solid tumours Phase I trial", ADISCTI, (20000520), Database accession no. 2000:12716, URL: STN, XP002766114 [A] 1-4 * the whole document *-
SEARCH- SEUFFERLEIN THOMAS ET AL, "Rapamycin inhibits constitutive p70-s6k phosphorylation, cell proliferation, and colony formation in small cell lung cancer cells", CANCER RESEARCH, (1996), vol. 56, no. 17, ISSN 0008-5472, pages 3895 - 3897, XP002766076 [A] 1-4 * the whole document *-
SEARCH- HIDALGO M ET AL, "THE RAPAMYCIN-SENSITIVE SIGNAL TRANSDUCTION PATHWAY AS A TARGET FOR CANCER THERAPY", ONCOGENE,, (200012), vol. 19, no. 56, doi:10.1038/SJ.ONC.1204091, ISSN 0950-9232, pages 6680 - 6686, XP009002368 [A] 1-4 * the whole document *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents